USE OF GENETICALLY MODIFIED T-LYMPHOCYTES EXPRESSING CHIMERIC ANTIGENIC RECEPTORS IN ONCOLOGY
The review summarizes the clinical experience of CAR T-cell therapy using for patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and solid tumors. The problems associated with CAR T-cell therapy of solid tumors and toxic effects of immunotherapy have been described.